Reports

Drug name	NICE TAs	Comments
Abatacept	TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed	Hospital use only
Abciximab injection	TA47 - Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (partially updated by CG94)	Hospital use only
Abemaciclib (Verzenios®)	TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Abiraterone tablets	TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen TA387 - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Acalabrutinib	TA689 - Acalabrutinib for treating chronic lymphocytic leukaemia
Adalimumab	TA187 - Infliximab and adalimumab for the treatment of Crohn's disease TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Adalimumab syringe	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA143 - Adalimumab , etanercept and infliximab for ankylosing spondylitis TA130 - Adalimumab , etanercept and infliximab for the treatment of rheumatoid arthritis TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Adalimumab#13.5	TA146 - Adalimumab for the treatment of adults with psoriasis TA392 - Adalimumab for treating moderate to severe hidradenitis suppurativa
Afatinib	TA310 - Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept	TA307 - Aflibercept in combination with ironotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	Hospital use only & negative TA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports